AB Science saw no growth in patent filings and highest growth of 0.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.99%. GlobalData’s DataBook provides a comprehensive analysis of AB Science’s patent filings and grants. Buy the databook here.
AB Science has been focused on protecting inventions in European Patent Office(EPO) with one publication in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent grants with nearly 50% of grants. The European Patent Office(EPO), and Spain(ES) patent Office are among the top ten patent offices where AB Science is filings its patents. Among the top granted patent authorities, AB Science has 50% of its grants in European Patent Office(EPO) and 50% in Spain(ES).
Roche could be the strongest competitor for AB Science
Patents related to rare diseases lead AB Science's portfolio
AB Science has the highest number of patents in rare diseases. For rare diseases no patents were filed and 100% of patents were granted in Q2 2024.
Prostate cancer related patents lead AB Science portfolio
AB Science has highest number of patents in prostate cancer.
For comprehensive analysis of AB Science's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.